WEDNESDAY, Aug. 21, 2019 (HealthDay News) -- Patients with a form of blood cancer known as multiple myeloma who haven't responded to other therapies might have a new weapon against the disease, researchers say.
A drug called selinexor appeared to help patients with the blood and bone marrow cancer, according to a clinical trial involving 122 people.
THURSDAY, Aug. 8, 2019 (HealthDay News) -- If a close relative has had blood cancer, you're more likely to get it, a large new study reports.
The researchers analyzed data from 16 million people in Sweden, including more than 153,000 diagnosed with blood cancer and more than 391,000 of their first-degree relatives: parents, siblings or children.
WEDNESDAY, July 3, 2019 (HealthDay News) -- More than 8.7 million years of life and about $94 billion in earnings were lost to cancer in the United States in 2015, researchers say.
Cancer is the nation's second-leading killer and is expected to cause nearly 607,000 deaths this year. These premature deaths and the lost productivity they cause impose a significant economic burden, the s...
WEDNESDAY, March 27, 2019 (HealthDay News) -- The chances of finding an unrelated bone marrow donor are higher for U.S. patients of European descent than for those of non-European descent, a new study finds.
A bone marrow transplant can sometimes help people with life-threatening blood cancers by replacing the patient's cells with healthy ones from a donor. A brother or sister with th...
MONDAY, May 7, 2018 (HealthDay News) -- Generic drugs tend to trigger big drops in the cost of their expensive, brand-name counterparts, but that has not been the case with the cancer drug commonly known as Gleevec (imatinib).
There's been only a small drop in the price of imatinib since a generic version was introduced to compete with Gleevec, a new study finds.
FRIDAY, Sept. 1, 2017 (HealthDay News) -- The U.S. Food and Drug Administration on Friday approved an altered dose of the drug Mylotarg to treat a distinctive type of acute myeloid leukemia -- CD33-positive AML.
An earlier version of the drug had been withdrawn from the market when health risks started to emerge.
Known generically as gemtuzumab ozogamicin, the drug received...